Dr. Reddy's Labs (RDY) - Return on Sales by Gross Profit

Official company branding of Dr. Reddy's Laboratories Limited (RDY)

The final gross margin of Dr. Reddy's Laboratories (RDY) demonstrates the efficiency of the Indian behemoth, which leverages low costs and vertical integration. Profit growth is based on the full production cycle of affordable medicines. However, stability depends on US drug approvals and factory oversight. The current value is 45.80, confirming the impact of Fed policy on production profitability.

RDY (drreddys.com) Gross Profitability history from 07/04/2022 to 11/20/2026

Financial and market metric breakdowns for Dr. Reddy's (RDY)

- stock price and consensus target price:
Fundamental valuation:Dr. Reddy's Lab
Signature product of drreddys.com

Dr. Reddy's Laboratories (RDY) minimizes regulatory risks through its global portfolio of generics and biosimilars. The absolute gross margin trend reflects the effectiveness of this diversification strategy. This metric is calculated as the difference between revenue and direct cost of goods sold, demonstrating the profit share before operating expenses. The stability of this metric confirms the business's ability to maintain production profitability amid pricing pressure.